Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersInfectious Disease Physician in Greensboro, NC
NPI: 1174735070Primary Practice Location
MOSES H. CONE MEMORIAL HOSPITAL, THE
618 S Main St, Reidsville, NC
Primary Employer
Cone Health Moses Cone Hospital
conehealth.com
HQ Phone
Get M.D. Cornelius's Phone Numberphone_androidMobile
Get M.D. Cornelius's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNC State Medical License
American Board of Internal Medicine
Infectious Disease
American Board of Internal Medicine
Internal Medicine
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 49 | 66 |
| 2 | 99223Initial hospital inpatient care, typically 70 minutes per day | 35 | 35 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 26 | 29 |
| 4 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 23 | 34 |
| 5 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 14 | 26 |
Authors: Babafemi Taiwo, Paul Sax, Beverly Sha, Roy Gulick, David Haas
Journal: Clin Infect Dis
Authors: Danielle Horridge, Aimee Wilkin
Journal: AIDS Behav
Authors: Michael Peluso, Florencia Segal, Jonathan Li, Paul Sax, Daniel Kuritzkes, Steven Deeks, Michael Keefer
Journal: J Infect Dis
Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Collaborators: AbbVie, National Institute of Allergy and Infectious Diseases (NIAID)
Intervention / Treatment: DRUG: Glecaprevir/Pibrentasvir (G/P)
Lead Sponsor: ViiV Healthcare
Collaborators: Janssen, LP
Intervention / Treatment: DRUG: Cabotegravir Tablets, DRUG: Rilpivirine Tablets, DRUG: Cabotegravir Injectable Suspension (CAB LA), DRUG: Rilpivirine Injectable Suspension (RPV LA), DRUG: BIKTARVY Tablets (BIK)
Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Intervention / Treatment: DRUG: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
